Navigation Links
Faruqi & Faruqi, LLP Notifies Investors of June 4, 2012 Lead Plaintiff Deadline for the Class Action Filed Against Chelsea Therapeutics International
Date:5/29/2012

NEW YORK, May 29, 2012 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Chelsea Therapeutics International, Ltd. ("Chelsea" or the "Company") (Nasdaq: CHTP).   

(Logo:  http://photos.prnewswire.com/prnh/20120119/MM38856LOGO)

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that:  (1) Chelsea's Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company's numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera's clinical trials, were materially false and misleading.

On February 13, 2012, Chelsea disclosed that the Food and Drug Administration ("FDA") had raised questions regarding the efficacy, size and duration of the Company's clinical trials for the drug Northera.  Furthermore, the FDA indicated that three deaths were potentially related to the drug's trials.  In the aftermath of these disclosures, Chelsea's stock price declined by more than 37 %. Then on March 28, 2012, the Company announced that its New Drug Application for Northera was rejected by the FDA. Upon this news, Chelsea shares fell more than 28%, to close at $2.62 per share on March 29, 2012.

Request more information now by clicking here:  www.faruqilaw.com/CHTP

Take Action

If you purchased Chelsea securities between November 3, 2008 and March 28, 2012 and would like to discuss your legal rights, visit www.faruqilaw.com/CHTP.  You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding Chelsea's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential matter.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Francis McConville, Esq.
fmcconville@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

 


'/>"/>
SOURCE Faruqi & Faruqi, LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Faruqi & Faruqi, LLP Announces Investigation of ZELTIQ Aesthetics, Inc.
4. Faruqi & Faruqi, LLP Announces Investigation of BioSante Pharmaceuticals, Inc.
5. Faruqi & Faruqi, LLP Announces Investigation of GenVec, Inc.
6. Masimo to Present at William Blair & Company 32nd Annual Growth Stock Conference
7. Acacia Pharma Announces Excellent Phase II Results for APD421 in Post-Operative Nausea & Vomiting (PONV)
8. MicroRNA Research to Trigger Tremendous Growth in Related Tools Market, Says Frost & Sullivan
9. Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market
10. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
11. Medical Device Developers - Network at MD&M East Next Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 2016 Research and Markets has announced the addition ... report to their offering. ... The report also analyses the market by the following Technology Types: ... for the US, Canada , Japan ... Latin America , and Rest of World. ...
(Date:12/9/2016)... 9, 2016 aTyr Pharma, Inc. (Nasdaq: LIFE ... Physiocrine-based therapeutics to address severe, rare diseases, today announced that senior ... Prescriptions for Success Healthcare Conference at the InterContinental Barclay Hotel in ... 2016, at 4:20 p.m. ET. About aTyr Pharma ... aTyr Pharma ...
(Date:12/9/2016)... 2016  Forge Therapeutics, Inc. today announced a ... EVT, TecDAX, ISIN: DE0005664809) to advance its novel ... of bacterial infections including those caused by drug ... attractive antibacterial target for more than the past ... starting points has hampered its progress. Forge has ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Flottman Company ... outserts. As a means of expanding capabilities Flottman has added a G&K ... individually code professional inserts (PIs) and patient package inserts (PPIs) that will marry ...
(Date:12/9/2016)... Hills, CA (PRWEB) , ... December 09, 2016 ... ... for young adults, celebrated its 10th anniversary with the grand opening of the ... California. The successful event spanned two days, December 2-3, and was attended by ...
(Date:12/9/2016)... Fort Lee, NJ (PRWEB) , ... December 09, ... ... the 2016 Founders Ball at The Pierre Hotel in New York, NY, on ... 700 friends, benefactors, dignitaries and physicians attended the annual event, which raised over ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... ... December 08, 2016 , ... After ... officially opened registration today for its 33rd Annual Issues & Research Conference, ... , The theme of the conference is “Persistent Challenges and New Opportunities: Using ...
Breaking Medicine News(10 mins):